Planning and preparation!. How you plan and prepare for your interview will clearly increase your opportunity for success!

As a recruiter, I have come across many job seekers who are willing to explore the job market but may not have any apparent reasons to leave their current jobs. These group of job seekers are the most likely to drop-out from a hiring process, even at offer stage, because they are more likely to accept a counter offer from their current employer. However, is it a wise decision to accept a counter offer? Will the underlying issues that prompted a person to passively explore job opportunities disappear or improve with the counter offer? Or is it all due to fear of change?

At Hayward Resourcing we believe in trying to do our little bit towards helping sustain the health of our planet and also contributing to causes less fortunate than ourselves. Some basic initiatives we embrace as an organisation:

Hayward Resourcing is an ethical and professional business that understands that everything within this world is interlinked. As a company we are delighted to have the opportunity to help those less fortunate than ourselves, and that is why we sponsor a child in Tibet through the Tibet Relief fund charity. Through the course of the year we also give to other charities like the WWF (Worldwide Fund for Nature) on a one-off basis as well as sponsoring a under 12's local football team and providing them with a new football kit for the season.

HONG KONG, May 31 (Reuters Breakingviews) - Chinese cash is set to fuel Europe’s green mobility challenge. More than one in five cars sold in the continent last year was electric, making the region the world’s second largest market for e-vehicles after China. That offers an enticing new opportunity for the battery makers from the People’s Republic, which already supply European brands such as Volkswagen (VOWG_p.DE), BMW (BMWG.DE) and Stellantis.

May 25 (Reuters) - Elon Musk's Neuralink received U.S. Food and Drug Administration (FDA) clearance for its first-in-human clinical trial, a critical milestone for the brain-implant startup as it faces U.S. probes over its handling of animal experiments. The FDA approval "represents an important first step that will one day allow our technology to help many people," Neuralink said in a tweet on Thursday, without disclosing details of the planned study. It added it is not recruiting for the trial yet and said more details would be available soon.